FTH · Faeth Therapeutics, Inc.

$32.34 +3.79 (+13.27%) At close · Aug 14

Market Cap

$835.68M

25.84M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
John Celebi	Former President and Chief Executive Officer	$481,928	—	—	$133,597	—	$644,975	$1,260,500
Edward van der Horst	Former Chief Scientific Officer	$357,083	—	—	$40,824	—	$351,283	$749,190
Stephanie Krebs	Former Chief Business Officer	$346,420	—	—	$44,535	—	$339,746	$730,701
Christopher W. Gerry	President and General Counsel	$398,181	—	—	$18,556	—	$17,863	$434,600
Josiah Craver	SVP, Finance	$372,650	—	—	$18,556	—	$18,504	$409,710

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
John Celebi	President and Chief Executive Officer	$535,600	—	—	$311,289	$268,804	$67,950	$1,183,643
Edward van der Horst	Chief Scientific Officer	$400,000	—	—	$109,948	$142,000	$15,768	$667,716
Stephanie Krebs	Chief Business Officer	$385,000	—	—	$40,602	$140,525	$18,259	$584,386

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
John Celebi	President and Chief Executive Officer	$532,167	—	$30,459	$99,554	$285,743	$64,366	$1,012,289
Edward van der Horst	Chief Scientific Officer	$382,667	—	$25,311	$82,962	$230,200	$17,942	$739,082
Erin Colgan	Former Chief Financial Officer	$423,667	—	$30,459	$99,554	$162,134	$18,388	$734,202

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
John Celebi	President and Chief Executive Officer	$512,500	—	$231,770	$537,420	$228,016	$59,176	$1,568,882
Robert Pierce	Former Chief R&D Officer	$421,154	—	$90,300	$298,251	—	$377,572	$1,187,277
Erin Colgan	Former Chief Financial Officer	$410,000	—	$90,300	$206,188	$132,020	$16,808	$855,316
Edward van der Horst	Chief Scientific Officer	$326,923	—	$63,210	$146,327	$103,543	$14,401	$654,404

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
John Celebi	President and Chief Executive Officer	$487,068	—	—	$6,116,715	$264,000	$41,912	$6,909,695
Robert Pierce	Former Chief R&D Officer	$410,000	—	—	$1,620,922	$167,700	$62,791	$2,261,413
Marie-Louise Fjaellskog	Former Chief Medical Officer	$345,497	—	—	$1,162,168	—	$151,987	$1,659,652
Erin Colgan	Chief Financial Officer	$317,812	—	—	$764,586	$123,600	$11,780	$1,217,778

Executive changes

Person	Role	Change	Effective	Filed
Josiah Craver	principal accounting officer	Appointed	2026-06-13	2026-06-15
Brian Stephenson	Chief Financial Officer	Appointed	2026-06-13	2026-06-15
Anand Parikh	President and Chief Executive Officer	Appointed	2026-06-13	2026-06-15
Kristian Humer	director	Appointed	—	2026-06-10
Bob Holmen	director	Appointed	—	2026-06-10
Phillip B. Donenberg	director	Appointed	2026-02-13	2026-02-13
Christopher W. Gerry	director	Appointed	2026-02-13	2026-02-13
Deneen Vojta, MD	Board of Directors	Resigned	2024-12-31	2024-10-30
Josiah Craver	principal financial officer and principal accounting officer	Appointed	2024-09-17	2024-09-20
Jessie English, PhD	Board	Resigned	2024-07-01	2024-06-27
Erin Colgan	Chief Financial Officer	Resigned	2024-04-10	2024-04-02
Bill Ringo	Interim Chair of the Nominating and Corporate Governance Committee	Appointed	2024-02-06	2024-02-08
Samuel Broder	Board of Directors	Resigned	2024-02-05	2024-02-08
Robert Pierce	Chief Research and Development Officer	Terminated	2022-12-07	2022-12-08
William Ringo	Class I director	Appointed	2022-03-08	2022-03-09
William Ringo	Chair of the Board	Appointed	2022-03-08	2022-03-09

Key facts CIK 1829802 CUSIP 81728A207 13F (30d) 49 filings 47 filers Visit website Investor relations